Two journal articles associated with Cassava Sciences have earned expressions of concern, according to Retraction Watch.
It reported in August that the law firm Labaton Sucharow submitted a citizen's petition to the US Food and Drug Administration to ask the agency to stop trials of the company's candidate Alzheimer's disease drug, simulfilam, due to concerns that images from lab-based studies supporting drug trials had been manipulated. The Wall Street Journal further reported last month that the US Securities and Exchange Commission was also investigating Cassava. Image manipulation experts told the Journal at that time that some western blot images in journal articles from the City University of New York's Hoau-Yan Wang and Cassava's Lindsay Burns appeared to show signs of tampering.
The Journal of Neuroscience has now appended expressions of concern to two studies, which it says are under investigation by CUNY. JNeurosci writes that it will wait until that investigation is complete before taking any other actions.
Retraction Watch adds that a third study at Neuroscience now has an editor's note that includes original western blot images that the journal says do not show signs of manipulation.